Report Description Table of Contents Anti-obesity Drugs Market Size & Overview The Anti-Obesity Drugs Market was valued at USD 6.6 billion in 2024 & is projected to reach USD 25 billion by 2030, expanding at a CAGR of 20% during the forecast period. This growth is fueled by the rising global obesity burden, launch of highly effective GLP-1 receptor agonists & dual-action agents. Anti-obesity Drugs Market Dynamics: Market Drivers Escalating Global Prevalence of Obesity & Metabolic Syndrome The prevalence of obesity continues to rise globally & is one of the most pressing public health challenges of our time. According to the World Obesity Atlas 2022, released by the World Obesity Federation, obesity is projected to affect 1 in 5 women & 1 in 7 men by 2030. In 2024, the NCD Risk Factor Collaboration estimated that over 1 Bn people worldwide are living with obesity, including approximately 880 Mn adults and 159 Mn children. The CDC estimates that 42% of adults were obese in the US in 2023. Clinical Success of New GLP-1 Receptor Agonists and Multi-Pathway Drugs The weight-loss treatment market is experiencing rapid growth due to high-efficacy drugs like Ozempic, Wegovy, Zepbound and Mounjaro. These drugs are extremely effective for weight management & blood glucose control. The obesity treatment market is projected to reach $200 Bn by 2031, with 16 new drugs expected to launch by 2029, contributing around $70 Bn to the GLP-1 segment. Market Restraints High Cost of Treatment & Limited Reimbursement Coverage The introduction of powerful anti-obesity medications offers hope in addressing the global obesity crisis. However, high costs & concerns over long-term healthcare expenses remain significant challenges to fully leveraging this advancement. Semaglutide 30-day course prices ranges from $804 (US) to $95 (Turkey); Liraglutide prices range from $1418 (US) to $252 (Norway), limiting affordability for uninsured populations. Many insurers do not cover anti-obesity drugs unless prescribed for comorbidities like diabetes reducing patient access. Currently, Medicare does not cover weight-loss medications, despite an estimated 41.5% obesity prevalence among the 47.4 Mn beneficiaries enrolled in Medicare Part D plans in 2020. Side Effects, Long-Term Safety Concerns, and Adherence Issues Some anti-obesity drugs are associated with side effects such as nausea, vomiting, pancreatitis & gallbladder issues. Long-term safety data is still evolving for newer agents, which raises caution among patients. Studies suggest that many patients discontinue treatment within 6–12 months, either due to side effects or plateaued weight loss, affecting real-world effectiveness & market retention. Market Opportunities Expansion into Cardiometabolic Disease Prevention & Comorbidity Management Anti-obesity drugs are increasingly being explored as preventive therapies for high-risk patients with prediabetes, hypertension & heart disease. GLP-1 analogs are being studied for slowing progression to type 2 diabetes & reducing major cardiovascular events (MACE) in obese patients without diabetes. These expanded indications could broaden payer coverage & patient eligibility, boosting long-term market growth. Increasing Acceptance & Policy Support for Obesity as a Chronic Disease Globally, there is a growing recognition of obesity as a treatable chronic condition, not merely a lifestyle issue. During the 2022 World Health Assembly, Member States endorsed the WHO Acceleration Plan to combat obesity, promoting nationwide initiatives through 2030. So far, 31 governments have taken the lead in implementing the plan to address the obesity crisis. Anti-obesity Drugs Market Segmentation: A Comprehensive Overview By Drug Type Peripherally Acting Drugs Centrally Acting Drugs Combination Drugs By Prescription Type Prescription Drugs Over-the-Counter (OTC) Drugs By Distribution Channel Hospital Pharmacies Online Pharmacies Retail Pharmacies By Region North America Asia Pacific Europe Latin America Middle East & Africa (MEA) Anti-obesity Drugs Market Segment Analysis: Growth Trends Across Categories: By Drug Type: Leading Segment: Peripherally Acting Drugs Peripherally acting drugs accounted for the largest share of the anti-obesity drugs market in 2024, contributing 47% of total revenue. These drugs, such as Orlistat, work by inhibiting fat absorption in the gastrointestinal tract without affecting the central nervous system, making them widely prescribed due to a favorable safety profile. Fastest-Growing Segment: Combination Drugs Combination drugs are the fastest-growing segment, projected to grow at a CAGR of 10.8% through 2030. These therapies, like naltrexone/bupropion (Contrave) & phentermine/topiramate (Qsymia), offer synergistic effects by targeting multiple biological pathways involved in appetite regulation & energy expenditure. By Prescription Type: Leading Segment: Prescription Drugs Prescription drugs dominated the market in 2024 with a share of approximately 72%. Given the complexity of obesity management and the requirement for physician supervision, especially when prescribing drugs that affect the central nervous system or have potential side effects, prescription-based therapies remain the standard of care. Fastest-Growing Segment: Over-the-Counter (OTC) Drugs OTC anti-obesity drugs are growing at a CAGR of 9.5% due to increasing demand for accessible, self-managed weight-loss solutions. Products such as Alli (OTC Orlistat) have seen wider consumer acceptance in regions with rising obesity prevalence and health awareness. Retail and online channels have further boosted availability, particularly in the U.S. and parts of Asia Pacific. By Distribution Channel: Leading Segment: Hospital Pharmacies Hospital pharmacies held the largest share in 2024, contributing about 40% of the global anti-obesity drug distribution. Hospitals play a central role in managing obesity linked to comorbidities like diabetes, hypertension & cardiovascular diseases. Fastest-Growing Segment: Online Pharmacies Online pharmacies are the fastest-growing distribution channel, with a CAGR of 12.3%. The convenience of home delivery, growing digital health literacy & patient preference for privacy in purchasing weight-loss treatments have driven this segment’s rapid expansion. E-commerce platforms are particularly popular in urban centers across the U.S., India, & China. By Region: Leading Region: North America North America held the largest market share in the anti-obesity drugs market in 2024, accounting for approximately 43% of global revenue. According to the CDC, 41.9% of U.S. adults were classified as obese in 2022, fueling strong demand for pharmacological interventions. Fastest-Growing Region: Asia Pacific APAC is the fastest-growing region, with a projected CAGR of 11.6% during the forecast period. Rising urbanization, sedentary lifestyles, and dietary shifts have contributed to a significant rise in obesity rates across China, India & Southeast Asia. Governments are increasingly launching public health campaigns & approving new anti-obesity therapies to address the growing burden, making the region a focal point for pharmaceutical expansion. Anti-Obesity Drugs Market Report Coverage Report Attribute Details Forecast Period 2024 – 2032 Market Size Value in 2024 USD 6.6 Billion Revenue Forecast in 2030 USD 25.0 Billion Overall Growth Rate CAGR of 20.0% (2024 – 2030) Base Year for Estimation 2023 Historical Data 2017 – 2021 Unit USD Billion, CAGR (2024 – 2030) Segmentation By Drug Type, By Prescription Type, By Distribution Channel, By Geography By Drug Type Peripherally Acting Drugs, Centrally Acting Drugs, Combination Drugs By Prescription Type Prescription Drugs, Over-the-Counter (OTC) Drugs By Distribution Channel Hospital Pharmacies, Online Pharmacies, Retail Pharmacies By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope US, Canada, Germany, China, India, etc. Market Drivers Rising obesity prevalence, increasing demand for weight management solutions, growing awareness of anti-obesity medications Pricing and Purchase Options Customized options available Key Players in the Anti-obesity Drugs Market Novo Nordisk Eli Lilly and Company Pfizer Inc. Boehringer Ingelheim Roche Holding AG Amgen Inc. Rhythm Pharmaceuticals Gelesis Inc. Currax Pharmaceuticals Zealand Pharma Frequently Asked Question About This Report Which region held the largest Anti-Obesity Drugs Market share? North America held the largest market share in 2024 due to high obesity prevalence, favorable regulatory approvals, and rapid adoption of new therapies. Which Application/Type had the largest Anti-Obesity Drugs Market share? Prescription-based GLP-1 receptor agonists dominated the market owing to their strong clinical efficacy and cardiometabolic benefits. How big is the Anti-Obesity Drugs Market? The market was valued at approximately USD 6.6 billion in 2024 & is projected to reach USD 25 billion by 2030, growing at a CAGR of over 20% during the forecast period. What are the key factors driving the growth of the Anti-Obesity Drugs Market? Key drivers include the global rise in obesity rates, success of GLP-1 receptor agonists, and increasing awareness of obesity-related health risks. Who are the Major Players in the Anti-Obesity Drugs Market? Major players include Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, Boehringer Ingelheim, Rhythm Pharmaceuticals, Zealand Pharma, Currax Pharmaceuticals, and Gelesis Inc. Source- https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity https://world-heart-federation.org/what-we-do/obesity/ https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-market-see-16-new-drugs-by-2029-report-estimates-2024-09-10/ https://academic.oup.com/healthaffairsscholar/article/2/6/qxae055/7661043 https://onlinelibrary.wiley.com/doi/10.1002/oby.23725 Table of Contents for the Anti-obesity Drugs Market Report Executive Summary • Market Overview • Market Attractiveness by Drug Type, Prescription Type, Distribution Channel, and Region • Strategic Insights from Key Executives (CXO Perspective) • Historical Market Size and Future Projections (2022–2032) • Summary of Market Segmentation by Drug Type, Prescription Type, Distribution Channel, and Region Market Share Analysis • Leading Players by Revenue and Market Share • Market Share Analysis by Drug Type, Prescription Type, and Distribution Channel Investment Opportunities in the Anti-obesity Drugs Market • Key Developments and Innovations • Mergers, Acquisitions, and Strategic Partnerships • High-Growth Segments for Investment Market Introduction • Definition and Scope of the Study • Market Structure and Key Findings • Overview of Top Investment Pockets Research Methodology • Research Process Overview • Primary and Secondary Research Approaches • Market Size Estimation and Forecasting Techniques Market Dynamics • Key Market Drivers • Challenges and Restraints Impacting Growth • Emerging Opportunities for Stakeholders • Impact of Macroeconomic and Technological Factors • COVID-19 and Post-Pandemic Analysis Global Anti-obesity Drugs Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Drug Type: o Peripherally Acting Drugs o Centrally Acting Drugs o Combination Drugs • Market Analysis by Prescription Type: o Prescription Drugs o Over-the-Counter (OTC) Drugs • Market Analysis by Distribution Channel: o Hospital Pharmacies o Online Pharmacies o Retail Pharmacies • Market Analysis by Region: o North America o Asia Pacific o Europe o Latin America o Middle East & Africa (MEA) North America Anti-obesity Drugs Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Drug Type • Market Analysis by Prescription Type • Market Analysis by Distribution Channel • Country-Level Breakdown: o United States o Canada o Mexico Asia Pacific Anti-obesity Drugs Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Drug Type • Market Analysis by Prescription Type • Market Analysis by Distribution Channel • Country-Level Breakdown: o China o India o Japan o South Korea o Rest of Asia Pacific Europe Anti-obesity Drugs Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Drug Type • Market Analysis by Prescription Type • Market Analysis by Distribution Channel • Country-Level Breakdown: o Germany o United Kingdom o France o Italy o Spain o Rest of Europe Latin America Anti-obesity Drugs Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Drug Type • Market Analysis by Prescription Type • Market Analysis by Distribution Channel • Country-Level Breakdown: o Brazil o Argentina o Rest of Latin America Middle East & Africa Anti-obesity Drugs Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Drug Type • Market Analysis by Prescription Type • Market Analysis by Distribution Channel • Country-Level Breakdown: o GCC Countries o South Africa o Rest of Middle East & Africa Key Players and Competitive Analysis • Novo Nordisk – Leader in Anti-obesity Drug Development • Eli Lilly and Company – Innovator in Weight Management Therapies • Pfizer Inc. – Major Player in Obesity Drug Pipeline • Boehringer Ingelheim – Strong Portfolio in Metabolic Diseases • Roche Holding AG – Expansion in Obesity Treatments • Amgen Inc. – New Entrant with Focus on Weight Loss Solutions • Rhythm Pharmaceuticals – Focus on Rare Genetic Obesity Treatments • Gelesis Inc. – Pioneering Device-Drug Combination Therapies • Currax Pharmaceuticals – Advancing Prescription Weight Loss Solutions • Zealand Pharma – Developing New Therapeutic Approaches for Obesity Appendix • Abbreviations and Terminologies Used in the Report • References and Sources List of Tables • Market Size by Drug Type, Prescription Type, Distribution Channel, and Region (2024–2032) • Regional Market Breakdown by Drug Type and Prescription Type (2024–2032) List of Figures • Market Dynamics: Drivers, Restraints, Opportunities, and Challenges • Regional Market Snapshot for Key Regions • Competitive Landscape and Market Share Analysis • Growth Strategies Adopted by Key Players • Market Share by Drug Type, Prescription Type, and Distribution Channel (2024 vs. 2032)